Pause in Trading
Filed with ASX · · 1 page · English
Summary by 6ix AI
Recce Pharmaceuticals Ltd. has announced a temporary pause in trading of its securities pending further announcement.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Correction to Appendix 4C and Quarterly Activities Report
- Patient Dosing Complete in Phase II ABSSSI Trial of R327G
- Regulatory Approval for Registrational Phase 3 R327G Trial
- Australia Patent Granted for RECCE Anti-Infectives
- AUD $6.75m R&D Rebate Approved
Later from Recce Pharmaceuticals
- Trading Halt
- Positive Phase II Data from Clinical Trial of R327 Gel
- Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway
- Japan Patent Allowance for RECCE Anti-Infectives
- Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals